MacroGenics (MGNX) to Release Earnings on Thursday

MacroGenics (NASDAQ:MGNX) is anticipated to post its quarterly earnings results after the market closes on Thursday, March 20th. Analysts expect MacroGenics to post earnings of ($0.23) per share and revenue of $34.17 million for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

MacroGenics Stock Performance

Shares of NASDAQ MGNX opened at $2.05 on Wednesday. The firm has a market cap of $128.66 million, a PE ratio of -1.30 and a beta of 2.12. The firm has a fifty day moving average of $2.73 and a 200 day moving average of $3.24. MacroGenics has a one year low of $2.04 and a one year high of $19.54.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.